scholarly journals Ibopamine – A New Alpha-Adrenergic and D1-Dopaminergic Drug

10.5772/58380 ◽  
2014 ◽  
Author(s):  
Italo Giuffre
Keyword(s):  
Dopaminergic Drug

ADRENERGIC INPUTS TO THE AMYGDALA AND THE CONTROL OF GONADOTROPHIN RELEASE

1979 ◽  
Vol 90 (3) ◽  
pp. 385-393 ◽  
Author(s):  
José Borrell ◽  
Flavio Piva ◽  
Luciano Martini
Keyword(s):  
Brain Stem ◽  
Dopamine Receptor ◽  
Serum Levels ◽  
Female Rats ◽  
Receptor Blocker ◽  
Dopaminergic Drug ◽  
Gonadotrophin Secretion ◽  
Biphasic Effect ◽  
Adrenergic Blocker ◽  
The Brain

ABSTRACT Drugs able to mimic or to antagonize the action of catecholamines have been implanted bilaterally into the basomedial region of the amygdala of adult castrated female rats. The animals were killed at different intervals after the implantation of the different drugs, and serum levels of LH and FSH were measured by radioimmunoassay. The results have shown that the intra-amygdalar implantation of the alpha-adrenergic blocker phenoxybenzamine induces a significant increase of the release both of LH and FSH. The implantation of the beta-adrenergic blocker propranolol brings about a rise of LH only. The dopamine receptor blocker pimozide stimulates the release of LH and exerts a biphasic effect (stimulation followed by inhibition) of FSH secretion. The alpha-receptor stimulant clonidine and the dopaminergic drug 2-Br-alpha-ergocryptine were without significant effects. From these observations it is suggested that the adrenergic signals reaching the basomedial area of the amygdala (possibly from the brain stem) may be involved in the modulation of gonadotrophin secretion.

Effect of intravenous amantadine on dopaminergic-drug-resistant freezing of gait

2011 ◽  
Vol 17 (6) ◽  
pp. 491-492 ◽  
Author(s):  
Young Eun Kim ◽  
Ji Young Yun ◽  
Beom S. Jeon
Keyword(s):  
Freezing Of Gait ◽  
Drug Resistant ◽  
Dopaminergic Drug

Benserazide and nomifensine in the diagnosis of prolactin-secreting pituitary adenomas

1982 ◽  
Vol 101 (2) ◽  
pp. 171-179 ◽  
Author(s):  
A. E. Pontiroli ◽  
G. Loda ◽  
A. Roggia ◽  
P. Scagliola ◽  
L. Falsetti
Keyword(s):  
Pituitary Adenoma ◽  
Pituitary Adenomas ◽  
Dopa Decarboxylase ◽  
Dopaminergic Drug ◽  
Normal Women ◽  
Synaptic Level

Abstract. Benserazide, an inhibitor of dopa-decarboxylase, stimulates prolactin (Prl) release in normal women and in puerperae; nomifensine, a dopaminergic drug able to release dopamine and to inhibit its re-uptake at the post-synaptic level, inhibits Prl release in the same subjects. Similar modifications of Prl release are evident in selected cases of non-tumoural hyperprolactinaemia, while neither drug modifies Prl release in patients with a Prl-secreting pituitary adenoma. The aim of our study was to compare the effect of these drugs in patients with a Prl-secreting pituitary adenoma, in patients with 'functional' hyperprolactinaemia and in patients with minor abnormalities of sellar tomography. Neither drug modified Prl release in patients with macro- or microadenomas; several patients in the remaining groups failed to respond to one or both tests, the concordance between the two tests averaging 75%. Patients responding to both tests, to one test or to neither test showed progressively higher basal Prl levels. Since benserazide and nomifensine can indicate the presence of a pituitary adenoma earlier than sellar tomography, our results indicate that patients with no Prl response to one or to both tests probably harbour a pituitary adenoma which cannot yet be revealed by sellar tomography.

scholarly journals A survey into the influence of dopaminergic drug exposure on ‘sense of presence’ symptoms in patients with parkinson's disease

BJPsych Open ◽  
2021 ◽  
Vol 7 (S1) ◽  
pp. S279-S280
Author(s):  
Emma Padfield ◽  
Hannah Potticary ◽  
Tim Segal
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Regression Analysis ◽  
Drug Exposure ◽  
Drug Dosage ◽  
Equivalent Dose ◽  
Dopaminergic Medication ◽  
Dopaminergic Drug ◽  
Sense Of Presence ◽  
The Relationship

AimsThe first objective was to estimate prevalence of sense of presence (SoP) experiences in patients with Parkinson's Disease (PD), including whether onset was prior to or after commencing dopaminergic medication. The second objective was to explore the relationship between frequency of SoP experiences and dopaminergic drug, drug dosage and length of drug exposure. The experimental hypothesis was that SoP symptoms in PD would present more frequently in patients treated longer and with higher dopaminergic drug doses.BackgroundPD is a debilitating neurodegenerative disorder. Psychiatric symptoms are common and associated with impaired quality of life and higher treatment costs. PD psychosis often starts with ‘minor hallucinations’, the most common being a false ‘sense of presence’ (SoP), the vivid sensation that someone else is nearby when nobody is there. SoP symptoms typically do not cause significant distress but may act as a prognostic marker for future severe psychosis and may prompt alteration of treatment or reduction in dopaminergic drug dosage. This study aimed to extend prior research by characterizing SoP further and investigating the link with dopaminergic medication.MethodThis was a retrospective, cross-sectional study. Twenty-one patients diagnosed with PD completed a questionnaire to identify presence of SoP symptoms, duration of symptoms, timing of onset related to dopaminergic treatment and the frequency of symptoms in relation to current levodopa equivalent dose (LED). Descriptive frequencies were compared using a two-tailed t-test. Multiple regression analysis was conducted to assess the relationship between frequency of SP experiences, levodopa equivalent dose and length of drug exposure.ResultSixteen of twenty-one patients reported experiencing SoP symptoms. Patients who had not experienced SoP symptoms had a significantly lower LED than those who had experienced these symptoms. There were no other significant differences between the groups. No statistical significance was shown on regression analysis; however our study was not adequately powered for the regression analysis as the number of participants was too low.ConclusionThis study confirms that SoP symptoms are common among patients with PD and supports a correlation between the total daily equivalent dose of levodopa and SoP symptoms. It does not provide evidence for a temporal relationship between onset of SoP symptoms and duration of dopaminergic treatment. The study was insufficiently powered and a larger study is required to investigate further.

scholarly journals Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder

2019 ◽  
Vol 236 (8) ◽  
pp. 2325-2336 ◽  
Author(s):  
Graham K. Murray ◽  
Franziska Knolle ◽  
Karen D. Ersche ◽  
Kevin J. Craig ◽  
Sanja Abbott ◽  
...  
Keyword(s):  
Drug Treatment ◽  
Obsessive Compulsive Disorder ◽  
Prediction Error ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Dopaminergic Drug

CV 205-502 in acromegaly

1993 ◽  
Vol 128 (5) ◽  
pp. 389-393 ◽  
Author(s):  
Pier Giorgio Chiodini ◽  
Roberto Attanasio ◽  
Renato Cozzi ◽  
Daniela Dallabonzana ◽  
Giuseppe Oppizzi ◽  
...  
Keyword(s):  
Open Study ◽  
Acute Administration ◽  
Factor I ◽  
Dopaminergic Drug ◽  
Lowering Effect ◽  
Retrospective Comparison ◽  
Significant Difference ◽  
Igf I ◽  
Resistant Patient ◽  
Long Acting

In a series of acromegalic patients the effects of CV 205-502, a new long-acting dopamine-agonist drug, on growth hormone (GH), insulin-like growth factor I (IGF-I) and prolactin (PRL) levels were evaluated in an open study. After acute administration of CV 205-502 (0.0375 mg, po) in 12 patients, GH levels did not change, whereas PRL values significantly decreased and remained suppressed for 24 h. In the 14 patients who underwent chronic CV 205-502 treatment (at daily doses of 0.1 50-0.600 mg/day given at bedtime or b.i.d. for up to 12 months), GH and IGF-I levels fell significantly from 60±17(mean±sem) μg/l to 28±10 μg/l and from 1127±84 μg/l to 738±57 μg/l. respectively (p<0.05). A retrospective comparison with the results obtained for the same patients during a previous chronic bromocriptine treatment (at daily doses of 5–20 mg given t.i.d. or q.i.d.) did not show any significant difference in the suppression of GH levels between the two treatments; no bromocriptine-resistant patient was CV 205502 sensitive, even at the highest CV 205-502 dose used. We conclude that in acromegaly chronic treatment with this new dopaminergic drug has a GH- and PRL-lowering effect that is similar to but more prolonged than that of bromocriptine, and normal or near-normal GH and IGF-I levels may be obtained in a few patients with b.i.d. administration. However, no GH-lowering effect is observed in bromocriptine-resistant patients.

scholarly journals Dopaminergic drug effects during reversal learning depend on anatomical connections between the orbitofrontal cortex and the amygdala

2013 ◽  
Vol 7 ◽  
Author(s):  
Marieke E. van der Schaaf ◽  
Marcel P. Zwiers ◽  
Martine R. van Schouwenburg ◽  
Dirk E. M. Geurts ◽  
Arnt F. A. Schellekens ◽  
...  
Keyword(s):  
Reversal Learning ◽  
Orbitofrontal Cortex ◽  
Drug Effects ◽  
Dopaminergic Drug

Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease

Neurology ◽  
2005 ◽  
Vol 65 (10) ◽  
pp. 1570-1574 ◽  
Author(s):  
A. H. Evans ◽  
A. D. Lawrence ◽  
J. Potts ◽  
S. Appel ◽  
A. J. Lees
Keyword(s):  
Drug Use ◽  
Parkinson Disease ◽  
Dopaminergic Drug ◽  
Factors Influencing

Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: Common implication of striatal neuropeptides

2010 ◽  
Vol 58 (1) ◽  
pp. 286-296 ◽  
Author(s):  
Mohamed Khalil Tamim ◽  
Pershia Samadi ◽  
Marc Morissette ◽  
Laurent Grégoire ◽  
Bazoumana Ouattara ◽  
...  
Keyword(s):  
Drug Treatment ◽  
Dopaminergic Drug
Sign in / Sign up

Export Citation Format

Share Document